Logo image of SRAX

SRAX INC (SRAX) Stock Fundamental Analysis

NASDAQ:SRAX - Nasdaq - US78472M1062 - Common Stock - Currency: USD

0.6  -0.98 (-62.03%)

After market: 0.62 +0.02 (+3.33%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SRAX. SRAX was compared to 282 industry peers in the Software industry. The financial health of SRAX is average, but there are quite some concerns on its profitability. SRAX has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SRAX has reported negative net income.
In the past year SRAX has reported a negative cash flow from operations.
SRAX Yearly Net Income VS EBIT VS OCF VS FCFSRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -10M -20M -30M

1.2 Ratios

SRAX has negative profitability rations, so we won't be analyzing them here.
SRAX's Return On Invested Capital of 0.04% is fine compared to the rest of the industry. SRAX outperforms 73.06% of its industry peers.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC 0.04%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRAX Yearly ROA, ROE, ROICSRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 50 -50 -100 -150 -200

1.3 Margins

The Operating Margin of SRAX (0.05%) is better than 73.06% of its industry peers.
Looking at the Gross Margin, with a value of 73.34%, SRAX is in the better half of the industry, outperforming 70.03% of the companies in the same industry.
In the last couple of years the Gross Margin of SRAX has grown nicely.
Industry RankSector Rank
OM 0.05%
PM (TTM) N/A
GM 73.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.58%
GM growth 5Y16.6%
SRAX Yearly Profit, Operating, Gross MarginsSRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SRAX is destroying value.
The number of shares outstanding for SRAX has been increased compared to 1 year ago.
SRAX has a better debt/assets ratio than last year.
SRAX Yearly Shares OutstandingSRAX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M 25M
SRAX Yearly Total Debt VS Total AssetsSRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of 0.23, we must say that SRAX is in the distress zone and has some risk of bankruptcy.
SRAX has a Altman-Z score of 0.23. This is in the lower half of the industry: SRAX underperforms 67.00% of its industry peers.
SRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.23
ROIC/WACC0
WACC10.1%
SRAX Yearly LT Debt VS Equity VS FCFSRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M -10M 20M -20M

2.3 Liquidity

SRAX has a Current Ratio of 1.13. This is a normal value and indicates that SRAX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of SRAX (1.13) is worse than 71.72% of its industry peers.
A Quick Ratio of 1.13 indicates that SRAX should not have too much problems paying its short term obligations.
SRAX has a Quick ratio of 1.13. This is in the lower half of the industry: SRAX underperforms 71.04% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
SRAX Yearly Current Assets VS Current LiabilitesSRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.18% over the past year.
The Revenue has grown by 109.34% in the past year. This is a very strong growth!
The Revenue has been decreasing by -5.67% on average over the past years.
EPS 1Y (TTM)42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%123.2%
Revenue 1Y (TTM)109.34%
Revenue growth 3Y39.3%
Revenue growth 5Y-5.67%
Sales Q2Q%37.85%

3.2 Future

SRAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 50.52% yearly.
The Revenue is expected to decrease by -5.17% on average over the next years.
EPS Next Y124.58%
EPS Next 2Y50.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-7.07%
Revenue Next 2Y-5.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
SRAX Yearly Revenue VS EstimatesSRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SRAX Yearly EPS VS EstimatesSRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 0 2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SRAX. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 1.95, the valuation of SRAX can be described as very cheap.
Based on the Price/Forward Earnings ratio, SRAX is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, SRAX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 1.95
SRAX Price Earnings VS Forward Price EarningsSRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -65.27
SRAX Per share dataSRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SRAX's earnings are expected to grow with 50.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.52%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SRAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SRAX INC

NASDAQ:SRAX (3/8/2023, 8:07:58 PM)

After market: 0.62 +0.02 (+3.33%)

0.6

-0.98 (-62.03%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)02-02 2023-02-02
Earnings (Next)04-03 2023-04-03
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners9.92%
Ins Owner Change0%
Market Cap15.79M
Analysts84.44
Price Target6.73 (1021.67%)
Short Float %0.63%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-107.64%
Min EPS beat(2)-107.64%
Max EPS beat(2)-107.64%
EPS beat(4)0
Avg EPS beat(4)-1488.54%
Min EPS beat(4)-3627.65%
Max EPS beat(4)-107.64%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-35.89%
Min Revenue beat(2)-49.18%
Max Revenue beat(2)-22.6%
Revenue beat(4)1
Avg Revenue beat(4)-15.97%
Min Revenue beat(4)-49.18%
Max Revenue beat(4)9.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.72%
EPS NQ rev (1m)47.14%
EPS NQ rev (3m)-130.83%
EPS NY rev (1m)-20.14%
EPS NY rev (3m)-20.14%
Revenue NQ rev (1m)-19.15%
Revenue NQ rev (3m)-19.15%
Revenue NY rev (1m)-40.35%
Revenue NY rev (3m)-40.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.95
P/S 0.55
P/FCF N/A
P/OCF N/A
P/B 0.64
P/tB 2.97
EV/EBITDA -65.27
EPS(TTM)-1.16
EYN/A
EPS(NY)0.31
Fwd EY51.34%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS1.09
BVpS0.94
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC 0.04%
ROICexc N/A
ROICexgc N/A
OM 0.05%
PM (TTM) N/A
GM 73.34%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.58%
GM growth 5Y16.6%
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 127.87%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z 0.23
F-Score4
WACC10.1%
ROIC/WACC0
Cap/Depr(3y)101.84%
Cap/Depr(5y)118.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%123.2%
EPS Next Y124.58%
EPS Next 2Y50.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)109.34%
Revenue growth 3Y39.3%
Revenue growth 5Y-5.67%
Sales Q2Q%37.85%
Revenue Next Year-7.07%
Revenue Next 2Y-5.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y100.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year322.13%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.54%
OCF growth 3YN/A
OCF growth 5YN/A